Source disclosure: February 24, 2026
Company 504A [504A.T]
TOKYO, Feb 24 (Pulse News Wire) – Innovacell (504A.T) filed its initial public offering (IPO) on the Tokyo Stock Exchange's Growth Market today. The company reported expected losses for the fiscal year ending Dec 2026, projecting a lower net profit attributable to parent shareholders of ¥0 (vs.
-¥3.463 billion last year). Revenue is forecast at ¥0, with operating losses of ¥0 (vs. ¥2.231 billion previously). Research and development expenses are anticipated to rise to ¥0 (up from ¥0 last year) due to ongoing clinical trials for ICEF15, targeting fecal incontinence.
Innovacell, founded in 2021, focuses on regenerative medicine and cell therapy. Its lead product, ICEF15, completed Phase IIb trials and is now in international multicenter Phase III trials across Europe and Japan. The company plans to commercialize ICEF15 post-approval, potentially through partnerships with pharmaceutical firms. The firm raised ¥0 via share issuance and warrant conversion ahead of the IPO, with funds allocated towards ICEF15’s development and operational costs.
Innovacell expects to finalize joint sales promotion agreements in Japan and continue clinical trial preparations for other pipeline products.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing